Hepatoid Adenocarcinoma of the Lung With EGFR Mutation and the Response to Tyrosine Kinase Inhibitor

被引：0
|
作者：
Chen, H. [1 ]
Wang, W. [2 ]
Li, X. [1 ]
Xu, C. [3 ]
Zhu, Y. [1 ]
Du, K. [1 ]
Fang, M. [2 ]
机构：
[1] Zhejiang Rongjun Hosp, Jiaxing, Peoples R China
[2] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[3] Fujian Canc Hosp, Fuzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Hepatoid adenocarcinoma; EGFR mutation; tyrosine kinase inhibitor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.02
引用
收藏
页码：S585 / S585
页数：1
相关论文
共 50 条
  • [1] Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors
    Chen, Hua-fei
    Wang, Wen-xian
    Li, Xing-liang
    Xu, Chun-wei
    Du, Kai-qi
    Zhu, You-cai
    Fang, Mei-yu
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : E217 - E219
  • [2] Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma
    Tatsuya Yoshida
    Genichiro Ishii
    Koichi Goto
    Kiyotaka Yoh
    Seiji Niho
    Shigeki Umemura
    Shingo Matsumoto
    Hironobu Ohmatsu
    Kanji Nagai
    Yuichiro Ohe
    Atsushi Ochiai
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1691 - 1700
  • [3] Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma
    Yoshida, Tatsuya
    Ishii, Genichiro
    Goto, Koichi
    Yoh, Kiyotaka
    Niho, Seiji
    Umemura, Shigeki
    Matsumoto, Shingo
    Ohmatsu, Hironobu
    Nagai, Kanji
    Ohe, Yuichiro
    Ochiai, Atsushi
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (10) : 1691 - 1700
  • [4] Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients
    Anja Lisa Riediger
    Steffen Dietz
    Uwe Schirmer
    Michael Meister
    Ingrid Heinzmann-Groth
    Marc Schneider
    Thomas Muley
    Michael Thomas
    Holger Sültmann
    Scientific Reports, 6
  • [5] Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients
    Riediger, Anja Lisa
    Dietz, Steffen
    Schirmer, Uwe
    Meister, Michael
    Heinzmann-Groth, Ingrid
    Schneider, Marc
    Muley, Thomas
    Thomas, Michael
    Sueltmann, Holger
    SCIENTIFIC REPORTS, 2016, 6
  • [6] Progression-free survival and response rate with EGFR tyrosine kinase inhibitor treatment according to EGFR mutation subtype in advanced lung adenocarcinoma
    Chai, C. S.
    Liam, C. K.
    Pang, Y. K.
    Kow, K. S.
    Wong, C. K.
    Poh, M. E.
    Tan, J. L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Correlation of papillary and bronchioloalveolar patterns in lung adenocarcinoma with EGFR mutation and response to tyrosine kinase inhibitors
    Beheshti, J.
    Mark, E.
    Sabo, E.
    Janne, P.
    Sequist, L.
    Jackman, D.
    Joshi, V.
    Iafrate, A.
    Wang, L.
    Meyerson, M.
    Lindeman, N.
    MODERN PATHOLOGY, 2007, 20 : 318A - 318A
  • [8] Correlation of papillary and bronchioloalveolar patterns in lung adenocarcinoma with EGFR mutation and response to tyrosine kinase inhibitors
    Beheshti, J.
    Mark, E.
    Sabo, E.
    Janne, P.
    Sequist, L.
    Jackman, D.
    Joshi, V.
    Iafrate, A.
    Wang, L.
    Meyerson, M.
    Lindeman, N.
    LABORATORY INVESTIGATION, 2007, 87 : 318A - 318A
  • [9] The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients
    Sarosi, Veronika
    Baliko, Zoltan
    Smuk, Gabor
    Laszlo, Terezia
    Szabo, Mariann
    Ruzsics, Istvan
    Mezosi, Emese
    PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 755 - 761
  • [10] Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
    Becker, Kevin
    Xu, Yiqing
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2014, 5 (04): : 560 - 567
12345